|
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
|
Sep 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
|
Mar 2017
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders
|
Jan 2017
|
J Natl Compr Canc Netw
|
myelodysplastic syndromes (MDS)
|
|
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
|
Aug 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.
|
Sep 2013
|
Eur J Haematol
|
myelodysplastic syndromes (MDS)
|
|
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.
|
Aug 2012
|
Crit Rev Oncol Hematol
|
aplastic anemia
|
|
The immune landscape of myelodysplastic syndromes
|
Nov 2016
|
Crit Rev Oncol Hematol
|
myelodysplastic syndromes (MDS)
|
|
The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation
|
Oct 2016
|
Biol Blood Marrow Transplant
|
myelodysplastic syndromes (MDS)
|
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications
|
Nov 2020
|
Cells
|
myelodysplastic syndromes (MDS)
|
|
The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes
|
Jan 2014
|
J Mol Diagn
|
myelodysplastic syndromes (MDS)
|
